Supplemental figure 1 ROS production in MM cell line (KMM1) treated with bortezomib and DCA. ROS production was marginally increased by DCA in combination.

Slides:

Advertisements

Similar presentations

Supplemental Figure 1 A No. at risk T T T

Advertisements

P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

Regulation of Cytochrome P450 2E1 Expression by Ethanol: Role of Oxidative Stress- mediated PKC/JNK/SP1 Pathway Mengyao Jin, Anusha Ande, Anil Kumar and.

Herceptin + 17-AAG Combination BT-474 Tumors

10 h5 h 0 h Supplemental Figure 1 14 h 16 h 24 h Untreated Supplemental Figure 1 Untreated cells were analyzed using live cell imaging microscopy. Time.

Supplemental Results Online Figure S1. Norepinephrine increases ROS production. (A): H9c2 cells were treated with 10  M norepinephrine and intracellular.

Supplemental Table 1 Source and authentication of cell lines.

SUPPLEMENT 2 This power point presentation reports analyses of RyR distribution measured by confocal microscopy in tangential sections of 6 SA node cells.

TREATED RESPONDER 8 TREATED NONRESPDR 6 14 UNTREATED RESPONDER 1 UNTREATED NONRESPDR PR (IHC)- PATIENTS (N=26) Ln(ER  ) mRNA level ≥ 12.47:

Figure Molecular Biology of the Cell (© Garland Science 2008)

Figure 14-1 Molecular Biology of the Cell (© Garland Science 2008)

The reading is 7.38 mm. The reading is 7.72 mm.

10 mm is the same as... 1 cm. 20 mm is the same as... 2 cm.

Supplemental Figure 1. Scatter plot of a PANC1 3D sphere CellTiterGlo assay plate. Each dot refers to the activity of a compound in a 1536-well microplate.

Supplemental Digital Content 2

A Untreated mM maphos, 48h 20 mM maphos, 48h 50 mM maphos, 48hh B

ONLINE SUPPLEMENTAL MATERIAL

Chapter 08 The T Cell Receptor: Proteins and Genes

a b c d Supplemental Figure S x108 IFU 2x108 IFU 28 28

Figure 1 Mast Cells per mm T-blue c-kit Rejecting Naive

Relations in Categorical Data

Bortezomib 1nM PU.1 GAPDH KMS12PE U266 U937 Supplemental Figure S1.

A B Supplementary Figure 3

Supplemental Figure S2: G2 arrest in MCF7-shPBK1 stable cell line

a b MCF-7 TR2 MCF-7 TR2 (Fold change) MTT Assay , (Fold change)

Figure S1 – supplemented figure A B

Supplementary Figure S2

Supplement Figure 3 SYF cells

Supplemental figure 1B Indicated cell lines were incubated with venetoclax (VEN) in combination with ara-C or idarubicin (IDA), for 48h and viability assessed.

SUPPLEMENTAL TABLE 1. Cell cycle profiles of HeLa cells treated

Supplemental Figure % of viable cells 10 5 RHPS4 RHPS4+GPI

Bortezomib sensitivity correlates with basal NF-κB activity in KP lung adenocarcinoma cell lines. Bortezomib sensitivity correlates with basal NF-κB activity.

pIRS1(S636/639) IRS1 actin PF Supplemental Figure S1

MARCH6 and TRC8 degrade membrane‐associated mCherry‐CL1

a b AP-1 Sp1 Nuclear extract Competitor (100X) CDCA 50 µM + - M

Supplementary Table 1.

Supplemental Figure 1A Pt Pt Pre-treatment

Supplemental Figure 1 a b c d.

Chadrick E Denlinger, MD, Michael D Keller, BS, Marty W Mayo, PhD, R

b. Bone marrow (CP) IM sensitive c. Bone marrow (CP) IM resistant

Supplementary Figure 1 HCT116 MOLT4

Supplemental Digital Content 2 – Figure 1

A CYP7A1 CYP7A AICAR (2 mM) * 0.8 mRNA expression

AUP, UBE2G2 and TRC8 facilitate the degradation of mCherry‐CL1 through a shared pathway AUP, UBE2G2 and TRC8 facilitate the degradation of mCherry‐CL1.

Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

Figure Overview.

Copyright © 2013 Elsevier Inc. All rights reserved.

Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Dharshan Sivaraj, Michael.

Reh cells, 24 hours c-Myc Ac-p53 b-actin

Schedule-Dependent Interaction between the Proteosome Inhibitor Bortezomib and the EGFR-TK Inhibitor Erlotinib in Human Non-small Cell Lung Cancer Cell.

Proteasomal inhibition suppresses palbociclib‐induced senescence phenotype Proteasomal inhibition suppresses palbociclib‐induced senescence phenotype ARepresentative.

Volume 74, Issue 6, Pages (September 2008)

Functional Enhancer Screening in Single Cells

A n.s. WT 4-1BB-/- B n.s. WT 4-1BB-/-

Supplemental Figure 4 A no agonist MALP2 PAM3CSK4 GFP WT F217S

Supplemental Figure 1A SMM Patient #1 MP-CTL % CD3+ CD8+ T Cells

C A B * * * * HCC1954 HCC1569 Supplementary-Figure S5 Tumor cells sc.

Induction of apoptosis by nelfinavir and bortezomib

Stimulation of mitochondrial embryo metabolism by dichloroacetic acid in an aged mouse model improves embryo development and viability Nicole O. McPherson,

Supplemental Fig. 1 Fig. S1. Requirement for both ALA treatment and irradiation to elicit a stress response. PC3 cells in serum-free medium were dark-incubated.

Figure 8. Measurement of levels of apoptotic proteins

Tipifarnib combined with bortezomib induces cell death in diverse multiple myeloma and AML cell lines. Tipifarnib combined with bortezomib induces cell.

Bone marrow stroma partially protects multiple myeloma and AML cell lines from tipifarnib- and bortezomib-induced cell death. 8226/S myeloma cells were.

Tipifarnib and bortezomib are synergistic in cytotoxicity assays

Combination CDN and PD-L1 mAb treatment of established MOC1 tumors produces consistent tumor rejection. Combination CDN and PD-L1 mAb treatment of established.

scrambled si-CLOCK scrambled si-CLOCK scrambled si-CLOCK scrambled

e a b c d unstimulated +fMLP T308P-Akt S473P-Akt Akt (min)

Figure 5-1 Molecular Biology of the Cell (© Garland Science 2008)

Presentation transcript:

Supplemental figure 1 ROS production in MM cell line (KMM1) treated with bortezomib and DCA. ROS production was marginally increased by DCA in combination with bortezomib. p< p=0.0023

Cut off is median (= ) p=0.24 (log rank) (N=27) Cut off is median (= ) (N=27) p=0.84 (log rank) p=0.29 (log rank) Cut off is median (= 9.98) (N=27) p=0.20 (log rank) Cut off is median (= 287) (N=27) Supplemental figure 2 Overall survival analysis of our cohort which was sub-grouped by expression of glycolysis- related genes except LDH. None of these genes serves as prognostic factor in our cohort.

LDHA (NM_ ) p=0.031 (Log-rank) PDK1 (NM_ ) p= (Log-rank) PDK1 ( AU ) p= (Log- rank) HIF1A (TT2, NM_ ) p= (Log- rank) GLUT1 (TT2, AI ) p= (Log-rank) GLUT1 (TT2, NM_006516) p= (Log- rank) MYC (TT2, NM_ ) p= (Log- rank) MYC (TT2, BF ) p= (Log- rank) Supplemental figure 3 Overall survival analysis in TT2 cohort (Re-analyzed using data by Zani et al.). Cases were sub- grouped by expression of LDHA, cMYC, GLUT1, HIF1A and PDK1. LDHA was the only prognostic factor.

p=0.0016p< p=0.9412p< Kruskal-Wallis test And Dunns multiple Comparison test * Supplemental figure 4 Expression of LDHA, cMYC, GLUT1, HIF1A and PDK1 in the 8 molecular subgroups of MM utilizing database deposited by Zhan et al. All genes except GLUT1 showed significant heterogeneous expressions. *: LDHA expression of CD2 group was significantly lowest than the other groups.

p= p=0.2774p=0.0805p= p= p= p=0.9207p= Supplemental figure 5 The association between the expression of LDHA, cMYC, GLUT1, HIF1A and PDK1 in 6 molecular subgroups of human myeloma cell lines utilizing data of Moreaux et al. There was no significant difference in expression of these genes within subgroups.